{"id":162,"date":"2005-05-25T08:14:01","date_gmt":"2005-05-25T08:14:01","guid":{"rendered":"https:\/\/palladiumcapital.com\/wp-padium\/?p=162"},"modified":"2013-07-26T01:53:30","modified_gmt":"2013-07-26T01:53:30","slug":"palladium-capital-advisors-advises-on-amarin-corp-plc%c2%b4s-17-8m-placement","status":"publish","type":"post","link":"https:\/\/www.palladiumcapital.com\/palladium-capital-advisors-advises-on-amarin-corp-plc%c2%b4s-17-8m-placement\/","title":{"rendered":"Palladium Capital Advisors advises on Amarin Corp PLC\u00b4s $17.8M Placement"},"content":{"rendered":"<p>May 25, 2005 \u00ad Amarin Corporation plc (NASDAQSC: AMRN) today announced that it has completed its previously announced registered direct offering with institutional and other accredited investors for gross proceeds of $17.8 million. The financing is intended to strengthen Amarin\u00b4s balance sheet and to provide funding for clinical trials. Miraxion, Amarin\u00b4s lead development compound, is in phase III development for Huntington\u00b4s disease and in phase II development for treatment of unresponsive depression. Palladium Capital Advisors acted as a consultant to ProSeed Capital Holdings, which served as placement agent for Amarin Corp.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>May 25, 2005 \u00ad Amarin Corporation plc (NASDAQSC: AMRN) today announced that it has completed its previously announced registered direct offering with institutional and other accredited investors for gross proceeds of $17.8 million. The financing is intended to strengthen Amarin\u00b4s balance sheet and to provide funding for clinical trials. Miraxion, Amarin\u00b4s lead development compound, is [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"_links":{"self":[{"href":"https:\/\/www.palladiumcapital.com\/wp-json\/wp\/v2\/posts\/162"}],"collection":[{"href":"https:\/\/www.palladiumcapital.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.palladiumcapital.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.palladiumcapital.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.palladiumcapital.com\/wp-json\/wp\/v2\/comments?post=162"}],"version-history":[{"count":0,"href":"https:\/\/www.palladiumcapital.com\/wp-json\/wp\/v2\/posts\/162\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.palladiumcapital.com\/wp-json\/wp\/v2\/media?parent=162"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.palladiumcapital.com\/wp-json\/wp\/v2\/categories?post=162"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.palladiumcapital.com\/wp-json\/wp\/v2\/tags?post=162"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}